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Background: In rodent models of Parkinson’s disease (PD), dopamine neuron loss is accompanied by increased
expression of angiotensin II (AngII), its type 1 receptor (AT1), and NADPH oxidase (Nox) in the nigral dopamine
neurons and microglia. AT1 blockers (ARBs) stymie such oxidative damage and neuron loss. Whether changes in
the AngII/AT1/Nox4 axis contribute to Parkinson neuropathogenesis is unknown. Here, we studied the distribution
of AT1 and Nox4 in dopamine neurons in two nigral subregions: the less affected calbindin-rich matrix and the
first-affected calbindin-poor nigrosome 1 of three patients, who were clinically asymptomatic, but had nigral dopamine
cell loss and Braak stages consistent with a neuropathological diagnosis of PD (prePD). For comparison, five clinically- and
neuropathologically-confirmed PD patients and seven age-matched control patients (AMC) were examined.
Results: AT1 and Nox4 immunoreactivity was noted in dopamine neurons in both the matrix and the nigrosome
1. The total cellular levels of AT1 in surviving dopamine neurons in the matrix and nigrosome 1 declined from
AMC>prePD>PD, suggesting that an AngII/AT1/Nox4 axis orders neurodegenerative progression. In this vein, the
loss of dopamine neurons was paralleled by a decline in total AT1 per surviving dopamine neuron. Similarly, AT1
in the nuclei of surviving neurons in the nigral matrix declined with disease progression, i.e., AMC>prePD>PD. In
contrast, in nigrosome 1, the expression of nuclear AT1 was unaffected and similar in all groups. The ratio of nuclear
AT1 to total AT1 (nuclear + cytoplasmic + membrane) in dopamine neurons increased stepwise from AMC to prePD to
PD. The proportional increase in nuclear AT1 in dopamine neurons in nigrosome 1 of prePD and PD patients was
accompanied by elevated nuclear expression of Nox4, oxidative damage to DNA, and caspase-3-mediated cell loss.
Conclusions: Our observations are consistent with the idea that AngII/AT1/Nox4 axis-mediated oxidative stress gives
rise to the dopamine neuron dysfunction and loss characteristic of the neuropathological and clinical manifestations of
PD and suggest that the chance for a neuron to survive increases in association with lower total as well as nuclear AT1
expression. Our results support the need for further evaluation of ARBs as disease-modifying agents in PD.
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The renin-angiotensin system (RAS) in the brain is
physically separated from the peripheral RAS by the
blood–brain barrier (BBB) [1]. Because it regulates blood
pressure and volume, RAS in the periphery is especially
important for survival in the case of hemorrhage [2]. For
this, circulating AngII binds to its type 1 receptor (AT1)
on vascular smooth muscle cells [3] to induce vasocon-
striction. The presence of a brain specific RAS and its
potential as a regulator of the brain’s response to stress
has been demonstrated in rodent [4], primate, and hu-
man brain [5]. Coordinated synthesis of AngII and AT1
in both neurons and glia in adult rat brain coincides
with localization of AT1 on endolysosomes [6], on mito-
chondria, and in nuclei [7]. The first hint of a nuclear-
delimited function of AngII came in the early 1970s,
when trafficking of radiolabelled AngII into the nuclear
compartment of smooth muscle cells was first reported,
suggesting that nuclear AngII/AT1 signaling influences
transcription [8]. In addition, AngII binding to AT1 in
the mature brain contributes to: i) the maintenance of
blood pressure [9]; ii) calcium-dependent hypothalamic
neuron depolarization [6]; and iii) dopamine release
from dopaminergic neurons [10,11]. On the other hand,
AngII binding to AT1 during brain development favors:
iv) neurogenesis [12] and v) differentiation of dopamine
neurons [13].
The original link between AngII/AT1 and dopamin-
ergic neurotransmission was established in the late
1970s by Simonnet and Giorguieff-Chesselet in a report
on AngII-evoked release of dopamine from rat striatal
slices [10]. Subsequently, autoradiography revealed AT1
binding sites in human nigral dopaminergic cell bodies
and in the striatum in dopaminergic terminals [14,15].
These findings raised, for the first time, the possibility
of the existence of a functionally active, self-contained
AngII/AT1 system in dopamine neurons in substantia
nigra that might be relevant to Parkinson’s disease. Indeed,
studies in rodent models of Parkinson’s demonstrated that
angiotensin receptor blockers (ARBs) such as losartan
protect dopamine neurons from the degenerative effects
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
in mice [4,16] and 6-hydroxydopamine (6-OHDA) in rats
[17,18]. The neurodegenerative consequences of the AT1
activation might come from AT1-mediated stimulation of
a multimeric NADPH oxidase (Nox) for production of
excessive levels of superoxide, as we demonstrated for
Nox2 in cultured rat dopaminergic cells [19] and for Nox4
in murine neural stem cells [12].
As rat dopamine neurons demonstrate an increase in
the numbers of AT1 in response to 6-OHDA treatment
[17] as well as with increased age, we posit here that
elevation of expression of AT1 presages dopamine neuron
dysfunction and loss. In parallel to these increases in theAT1 following intrastriatal 6-OHDA injection, p47 and
Nox2, which are cytoplasmic and catalytic Nox sub-
units, respectively, are also elevated; thus, Nox is acti-
vated and oxidative damage to macromolecules ensues
[20]. These responses are not limited to 6-OHDA
models, as we have reported that a selective dopamin-
ergic neurotoxin, 1-methyl-4-phenylpyridinium (MPP
+), elevates expression of Nox2 and promotes Nox2-
dependent superoxide generation in a midbrain-derived
rat dopaminergic cell line and that these pathogenic
effects are reduced by losartan [19]. These findings are
consistent with a role for AngII/AT1/Nox-mediated
oxidative stress in the initiation and progression of neu-
rodegeneration in neurotoxin-induced Parkinson models.
Our earlier report on the expression of p47 and Nox2
in dopaminergic neurons in the adult human substantia
nigra [19], together with a demonstration in a human
brain by Garrido-Gill and colleagues of nigral intra-
neuronal RAS [5], support the notion of a direct link
between AngII/AT1 and Nox/superoxide generation in
human dopamine neurons. Until now, there existed
only a single report suggesting that in humans the
response of the brain RAS to degenerative conditions
results in a change in AT1 numbers. Although the
phenotypic identity of the neural cells examined was
not identified by this 1996 report by Ge and Barnes
[21], they did report that relative to that present in
age-, sex-, and post-mortem interval-matched neuro-
logically normal individuals, there is a marked reduc-
tion in AngII binding to AT1 in the caudate, putamen,
and substantia nigra in brains of Parkinson patients.
In order to identify and characterize AT1-related
changes as a function of neurological and neuropatho-
logical changes characteristic of PD, we studied the
distribution and levels of expression of AT1 in sub-
stantia nigra of three groups of patients: those who had
neuropathological changes consistent with PD, but
were asymptomatic as to motor dysfunction (pre-PD);
those with frank PD; and patients of similar ages who
died neurologically and neuropathologically intact
(AMC). For a comparison of data from these cases,
we developed a semi-quantitative immunofluorescence
microscopy-based strategy for systematic analysis of
the AT1 within subdivisions of the substantia nigra
with regard to its steady state levels as well as its spe-
cific subcellular location in dopamine neurons in nigral
tissue sections. The rationale for examining the matrix
and nigrosome 1 subdivisions arose from earlier dem-
onstrations by Damier and colleagues that human sub-
stantia nigra is compartmentalized into distinct zones
termed nigrosomes 1–5 (calbindin poor) and matrix
(calbindin rich) [22] and that the nigrosome 1 is the site of
the earliest loss of dopamine neurons in Parkinson’s [23].
Reasoning that these nigral compartments might engender
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pathway, we examined these distinct nigral regions and
found that the whole-cell levels of AT1 in dopamine
neurons were gradually reduced in both nigral matrix
and nigrosome 1 in a pattern indicative of a disease-
related progression (AMC>prePD>PD). In contrast to
the attendant and similar losses of AT1 in dopamine
neurons and their nuclei in neurons of the nigral
matrix, the nuclear AT1 profile in neurons of nigro-
some 1 differed distinctly, i.e., the ratio of nuclear/total
neuron AT1 expression was elevated with disease pro-
gression. Disease progression was also associated with
increased levels of Nox4, StressMarq-detected oxida-
tive damage to nucleic acids, and active caspase-3 in
the nuclei of dopamine neurons.
Materials and methods
Case selection and neuropathological assessment
All brain tissues (n = 15) examined were from the
Human Brain Bank at the Reynolds Institute on Aging
at the University of Arkansas for Medical Sciences.
Specific cases were selected using two criteria: i) pres-
ence or absence of motor symptoms characteristic of
PD and ii) presence or absence of depigmentation of
the nigra – an index of dopamine neuron survival.
Patients who were presymptomatic (i.e., showed no
motor symptoms), but displayed a detectable depig-
mentation of the nigra as well as α-synucleinopathy
identified using BrainNet Europe Consortium staging
protocols [24,25], i.e., Braak stage 6 (ages 69–79, 3
males) were classified as prePD patients. Patients with
advanced disease (evident motor symptoms) combined
with severe depigmentation of the nigra and Braak
stage 6 (ages 66–85, 3 males, 2 females) were classified
as PD. Neurologically and neuropathologically normal
patients of similar age (Braak stage 0, ages 67–87, 6
males, 1 female) were used as age-matched controls
(AMC) (Table 1). Autopsy tissues studied are exempt
from Institutional Review Board (IRB) review under
46.101 5(b), and this study was approved as an exempt
study by the University of Arkansas IRB.
Tissue preparation, immunohistochemical detection of
Calbindin D28k, and immunohistofluorescence
Brains were fixed in formalin (no methanol) for two
weeks prior to further processing. Formalin-fixed mid-
brain was blocked in a transverse plane and paraffin-
embedded prior to cutting 7 μm-thick sections of the
substantia nigra at its intermediate to caudal levels and
processed as previously described [26]. The intermedi-
ate substantia nigra was defined as that coinciding with
the exit of Cranial Nerve III. All antibodies used, clone
(m =monoclonal) or type (p = polyclonal), recognized
epitope(s), methods for unmasking epitopes, dilutions,and procurement sources are listed in Table 2. The
primary antibody for AT1 detection was a goat IgG
from Santa Cruz (Cat# sc-1173-G). For each case, at
least six sections from substantia nigra were cut, and
at least one section immunostained for each of the
following: i) TH/AT1/DAPI; ii) Nox4/AT1/DAPI; iii)
StressMarq/AT1/DAPI; iv) caspase-3/TH/DAPI; v) α-
synuclein; and vi) calbindin D28k. For select AMC,
prePD, and PD cases additional sections were cut and
processed for co-immunodetection of AT1 with one of
the following GFAP, Iba1, Nup62, Pan-Neuronal whole
neuron marker, or S100B. Calbindin D28k immunohis-
tochemistry was used to identify nigrosomes in all 15
patients examined. Photomicrographs demonstrating
position of nigrosomes 1–4, located in intermediate and
caudal substantia nigra are identifiable as dark areas,
i.e., calbindin-poor regions adjacent to bright areas that
are calbindin rich (Figure 1).
Sections that were used for immunohistofluorescence
were treated with 0.1% Sudan Black B (Sigma) in 70%
ethanol to block lipofuscin autofluorescence. All immu-
noreactions were by overnight incubation at room
temperature. Appropriate Alexa Fluor-tagged secondary
antibodies were diluted in antibody diluent 1:200 (DAKO),
and sections were incubated for 60 minutes, washed three
times for 5 minutes each in distilled water, and cover-
slipped with prolong Gold with DAPI (Invitrogen) for
DNA/nuclear staining. For each set of slides, one no
primary antibody control section was treated exactly the
same, including the secondary antibody. On two occa-
sions, prior to immunohistofluorescence procedure on
human SN sections, additional controls were run by
pre-absorbing primary antibody against AT1 at 4°C
overnight with AT1 blocking peptide (Santa Cruz Cat#
sc-1173 P) against which the primary antibody was
raised. The weight ratio of the primary AT1 antibody to
the AT1 blocking peptide that totally prevented detec-
tion of the AT1 in SN was 1:50 (0.5 μg antibody:25 μg
blocking peptide). At ratios of 1:20 and 1:10, the block-
ing peptide was also effective in lowering the intensity
of AT1 fluorescence, but to a lesser extent than the
complete AT1 signal blockade seen at the antibody to
peptide ratio of 1:50 (data not shown). To confirm the
staining pattern obtained with the primary anti-AT1
antibody from Santa Cruz, we have performed immuno-
histofluorescent staining of select sections from human
brain with an alternative primary anti-AT1 antibody
made in goat (Sigma Cat# SAB2500038).
Semiquantitative assessment of AT1 in nigral
TH-immunoreactive dopamine neurons
The expression of AT1 in TH-immunoreactive dopa-
mine neurons of human substantia nigra was quantified
using similar methods to those that we have previously
Table 1 Age, gender, clinical diagnosis, cause of death, post-mortem interval, and brain weight for control, prePD, and
PD cases
All prePD and PD cases are α-synuclein Braak stage 6
Case Group Age (y)/
gender
Clinical
diagnosis
Cause of death PMI (h) Brain
weight (g)
1 AMC 67/M Leukemia Pneumonia 5.5 1450
2 AMC 78/M Atherosclerosis Pulmonary Embolism 19.0 1070
3 AMC 87/F Atherosclerosis/diabetes Renal failure 13.0 NA
4 AMC 85/M Adenocarcinoma Metastasis 11.0 1210
5 AMC 76/M Atherosclerosis/diabetes Heart failure 3.0 1480
6 AMC 87/M Atherosclerosis Aneurysm rupture 5.0 1375
7 AMC 79/M Atherosclerosis Heart failure 22.5 1550
8 PrePD 79/M AD Pneumonia 14.5 1100
9 PrePD 86/M COPD pneumonia 20.5 1175
10 PrePD 69/M Primary aphasia Unknown <12.0 1475
11 PD 85/M PD/dementia Heart failure 5.5 NA
12 PD 76/M PD/dementia Pneumonia 7.0 1490
13 PD 84/M PD/dementia Unknown 1.5 1250
14 PD 66/F PD/dementia Unknown 10.0 1050
15 PD 77/F PD/AD Pneumonia 5.5 1075
Abbreviations: COPD chronic obstructive pulmonary disease and PMI post-mortem interval.
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GFAP-immunoreactive astrocytes and Iba1-immunoreactive
microglia [26-28]. In the current study, each of the nigral
sections examined contained both the calbindin poor nigro-
some 1 region as well as the calbindin rich matrix (Figure 1).
In each nigral section, the nigrosome 1 and matrix
regions were identified based on the level of calbindinTable 2 Antibodies used and antigen unmasking procedures
Antibody Clone/type Epitope
α-synuclein 42, Mouse IgG1 Rat α-synuclein 15-123
AT1 p Goat Synthetic peptide mapping @
N-terminus of human AT1
Calbindin D28k p Rabbit Rat calbindin D28k
DNA/RNA
damage
m Mouse 15A3 8-hydroxy-guanosine-BSA and -casein
conjugates
GFAP p Chicken Bovine full length native protein
Iba1 p Rabbit Synthetic peptide of C-terminus of
Iba1 conserved between humans,
rats, and mice
Nup62 m Mouse Human nucleoporin 62 aa. 24-178
Pan-Neuronal m Mouse Whole neuron marker
Nox4 m Rabbit Synthetic peptide within NADPH binding
domain of human Nox4 (Q9NPH5)
S100B Rabbit 35HT3-10
Tyrosine
hydroxylase
p Rabbit Synthetic peptide mapping @ N-terminu
of human TH
Abbreviations: m monoclonal and p polyclonal.D28k immunodetection, and within each, a single square
Area Of Interest (AOI) spanning 9.0 mm2 was identified.
Each AOI was further parcelated into fields of interest
each equal to 37638.6 μm2 and representing the entire
area of a 40× photomicrograph. Three consecutive photo-
micrographs, one of each fluorescence channel starting
with red (TRITC for AT1), followed by green (FITCemployed
Unmasking Dilution Source
70% Formic acid for 10 min 1:500 Becton-Dickenson
Microwave in 10 mM citrate buffer
pH 6 for 30 min
1:100 Santa Cruz
Microwave in 10 mM citrate buffer
pH 6 for 30 min
1:500 Swant
Microwave in 10 mM citrate buffer
pH 6 for 30 min
1:100 StressMarq
Trypsin @37°C for 10 min 1:1000 Aves Labs
Microwave in 10 mM citrate buffer
pH 6 for 30 min
1:400 Wako
Microwave in 10 mM citrate buffer
pH 6 for 30 min
1:50 BD Transduction
Laboratories
Microwave in 10 mM citrate buffer
pH 6 for 30 min
1:500 Millipore
Microwave in 10 mM citrate buffer
pH 6 for 30 min
1:200 Abcam
Trypsin @37°C for 10 min 1:1000 Dr. Linda Van Eldik
s Microwave in 10 mM citrate buffer
pH 6 for 30 min
1:1000 Pel-Freez
Figure 1 Nigrosomes at specific rostrocaudal levels of the adult human SN. Nigrosomes were identified in all 15 patients examined by
Calbindin D28k immunohistochemistry in the intermediate (A, C, and E) and caudal (B, D, and F) SN. In these negative images, nigrosomes are
depicted as dark areas (i.e., calbindin-poor) and numbered 1–4. Matrix is calbindin-rich and appears white. We have examined one AOI for nigrosome 1
and another AOI for matrix for each case studied. Substantia nigra (SN); Red nucleus (RN). Scale bar is 1000 μm.
Zawada et al. Acta Neuropathologica Communications  (2015) 3:9 Page 5 of 16for TH), and ending with blue (DAPI for nuclei) were
captured for each section at predetermined and fixed
exposure settings for each fluorophore (TRITC at
500 ms; FITC at 2 s; DAPI at 200 ms) using a Nikon
Eclipse E600 microscope equipped with a CoolSNAP™
EZ monochrome CCD camera (Photometrics). For each
patient, all neurons immunopositive for TH were
counted in one AOI within matrix and one AOI within
nigrosome 1 of one section, i.e., within the same AOIs
that were used for AT1 detection and intensity meas-
urement. For a neuron to be counted it had to be TH+
and contain a DAPI-labelled nucleus. The TH+ neuron
counts (density) are reported as TH+ neurons/mm2.
In order to measure the intensity of AT1 expression in
dopamine neurons, all TH- immunopositive neurons
(FITC fluorescence) within the nigrosome 1 AOI and
within the matrix AOI in each photomicrograph had
their perimeter manually outlined with an area-polygon
selection tool in Nikon software NIS-Elements BR3 soft-
ware (Nikon). To quantify the intensity of AT1 in each
whole dopamine neuron profile, the outline of each
dopamine neuron profile (FITC channel) was copied andpasted into the TRITC fluorescence channel exactly in
the same location on the photomicrograph as that for
the FITC channel. Similarly, the intensity of nuclear AT1
was measured by outlining the nuclei (DAPI fluores-
cence) of dopamine neurons and copying and pasting
the resulting outline into the TRITC channel. For the
AT1-related fluorescence intensity quantification used as
an index of the AT1 abundance, the sum intensity in
each neuron within the AOI and within each nucleus
were averaged for the group of neurons in the matrix
and in nigrosome 1 for comparisons of AT1 intensity
per neuron and per nucleus in these two nigral regions.
The number of dopamine neurons and their nuclei
examined within AOIs was within the following ranges:
i) in AMC cases from 41 to 154 in matrix and from 39
to 140 in nigrosome 1; ii) in prePD cases from 71 to 147
in matrix and from 21 to 47 in nigrosome 1; and iii) in
PD cases from 10 to 151 in matrix and from 10 to 44 in
nigrosome 1. In total, 2086 dopamine neurons were
analyzed using immunofluorescence intensity measures
in order to estimate AT1 expression levels in dopamine
neurons and their nuclei.
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stress in nigral TH- and AT1-immunoreactive dopamine
neurons and AT1 detection at the nuclear membrane
The numbers of nuclei in pigmented neurons that con-
tained both Nox4/AT1 and StressMarq/AT1 immunore-
activity, or contained neither were counted in three
fields captured at 40× magnification from both matrix
and nigrosome 1 in each patient. The numbers of
dopamine neuron nuclei examined within these three
fields were as follows: i) in AMC cases 104; ii) in prePD
cases 81; and iii) in PD cases 179. In total, 147 dopa-
mine neurons were analyzed to detect the presence of
nuclear Nox4 and 103 dopamine neurons were ana-
lyzed to detect the presence of nuclear StressMarq. To
determine correlations between the presence of Nox4
and StressMarq in AMC, versus prePD, versus PD, the
percentage of Nox4 and StressMarq immunoreactive
nuclei was determined and expressed as a percentage
of affected neurons. To determine if the nuclear AT1 was
associated with nuclear membrane, selected tissue sections
were co-immunoreacted with antibodies targeting AT1
and nucleoporin 62 (Nup62) and to assess the degree of
injury associated changes in dopamine neurons, one
tissue section of substantia nigra from each patient was
immunoreacted with active caspase-3 antibody allowing
detection of the intensity and sub-cellular localization
of caspase-3 in matrix and nigrosome 1 relative to
neurological and neuropathological change.
Statistical analysis
Data are expressed as mean ± SEM with significance
set at p ≤ 0.05. To assess differences among groups,
data were analyzed by one way ANOVA followed by
Student-Newman-Keuls post hoc analysis in SigmaPlot
11 scientific graphing and data analysis program (Systat
Software Inc.).
Results
AT1 in dopamine neurons, microglia, astrocytes, and
vascular smooth muscle cells in the substantia nigra of
neurologically and neuropathologically normal patients
(AMC) as well as in prePD and PD patients
In all patients examined, irrespective of their health
status (AMC, prePD, or PD), we found AT1 in all
dopamine neurons. Adding prominence to the brain’s
AT1 expression profile is the fact that AT1 was also
expressed in all neurons as evidenced by the AT1 im-
munoreactivity present in neurons that were immuno-
positive for a Pan Neuronal marker, but were not
pigmented and/or immunopositive for TH. An ex-
ample of such neuronal AT1 expression is illustrated in a
nigral section from a 69-year old prePD patient (Figure 2A).
In addition, in all patients examined, AT1 immunoreactivity
was present in both Iba1-immunoreactive microglia(Figure 2B) and S100B- and GFAP-immunoreactive as-
trocytes (Figure 2C-G). AT1 expression was also noted
in vascular smooth muscle cells of the blood vessels
within substantia nigra (Figure 2C). The AT1 expression
pattern identified with the primary anti-AT1 antibody
from Santa Cruz was identical to that detected in select
sections with an alternative anti-AT1 antibody pur-
chased from Sigma (data not shown).
Loss of dopamine neurons in nigrosome 1 and in the matrix
correlates with progression from AMC to prePD to PD
The numbers of dopamine neurons in nigrosome 1 of
prePD and in PD patients were markedly less (p = 0.002
and p < 0.001, respectively) than corresponding dopa-
mine neuron counts in nigrosome 1 in AMC patients.
Unlike the findings in nigrosome 1, the numbers of
dopamine neurons in the matrix did not correlate with
clinical diagnosis, although there was a trend toward
reduction in these neurons in PD patients (Figure 3).
These differences in cell loss between the matrix and
nigrosome 1 suggest that the AT1 levels, distribution,
and actions might also be differentially affected in neu-
rons in these two nigral compartments, which is con-
sistent with the view that the earliest signs of nigral
dopamine neuron loss in Parkinson’s occur in the
nigrosome 1 [23].
Total cellular AT1 expression in nigral dopamine neurons
is reduced with disease progression, but nuclear AT1 in
such cells in nigrosome 1 is unchanged
The observation by Ge and Barnes [21] of a significant
reduction in ligand binding to the AT1 in tissue samples
from the putamen, caudate, and substantia nigra of
Parkinson’s patients as compared to such ligand binding
in tissues from neurologically normal control patients
aroused our suspicion that neurons might substantially
contribute to such changes in the AT1 expression. We
found that the intensity of AT1 immunoreactivity in sur-
viving dopamine neurons in both matrix (Figure 4A-F)
and in nigrosome 1 (Figure 4G and H) declined stepwise
from neurologically intact patients in a disease-related
fashion (AMC>prePD>PD). In fact, in dopamine neu-
rons in nigral matrix of some patients with advanced
PD, AT1 expression was almost non-existent (Figure 4C
and F). A comparison of the expression of AT1 in dopa-
mine neurons in nigral matrix and nigrosome 1 of tissue
from control patients, or from either prePD or PD,
demonstrated that the total AT1 immunofluorescence
intensity per dopamine neuron was substantially reduced
(p < 0.001) (Figure 4I).
Although AT1 immunoreactivity was most evident in
dopamine neurons, it was also present in non-TH-
immunoreactive neural cells, and this immunoreactivity
followed a most-to-least order from perinuclear, to
Figure 2 Intracellular AT1 in neural and vascular cells of the
adult human substantia nigra. AT1 is shown to be highly expressed
in nigral dopamine neurons (A), in Iba1-positive microglia (B), and in
S100B- (C) and GFAP-immunoreactive astrocytes (D-G) of a 69 years
old prePD patient. AT1 is also detected in vascular smooth muscle cells
in the tunica media (i.e., the medial layer) of the blood vessel wall (C).
Scale bars are 20 μm.
Figure 3 The number of TH-positive neurons counted in matrix
and nigrosome 1 areas of SN in neurologically intact individuals
(AMC) and in prePD and in PD patients. TH+ neurons were
examined in two 9.0 mm2 areas of the SN, viz., in the matrix region,
which is calbindin-rich, and nigrosome 1, a calbindin-poor region.
Data are expressed as mean ± SEM; * denotes significant differences
(p < 0.05) between nigrosome 1 in prePD and in PD as compared to
AMC. The number of TH+ neurons in the matrix was not significantly
altered with clinical diagnosis.
Zawada et al. Acta Neuropathologica Communications  (2015) 3:9 Page 7 of 16cytoplasmic, to intranuclear (Figure 5A-B). Many nuclei of
dopamine neurons, particularly in tissues from PD and
prePD patients, exhibited AT1 accumulations, which
appeared to penetrate the nucleus and coincide with
irregularly-shaped nuclei (Figure 5C). In addition to
this apparent intranuclear localization, AT1 was also
noted within the nuclear envelope as evidenced by
co-localization of AT1 immunoreactivity with an inte-
gral subunit of the nuclear pore complex, nucleoporin
p62 [29,30] (Figure 5D-G). AT1 co-localized with p62 in
neurons and numerous smaller cells in all AMC, prePD,
and PD cases examined. Quantification of AT1 im-
munofluorescence within nuclei of dopamine neurons
in neurologically intact individuals/AMC and in prePD
and in PD patients (Figure 5H) showed that the density
of nuclear AT1 in nigrosome 1 remains constant as dis-
ease progresses whereas, in the matrix, the abundanceof nuclear AT1 is gradually reduced as a function of
disease progression following the trajectory of the total
AT1 decline within the entire neuron (Figure 4I).
Consequently, the ratio of nuclear AT1 to total AT1
(nuclear + cytoplasmic + membrane) in dopamine neu-
rons of nigrosome 1 (Figure 6) increased stepwise from
AMC (0.274)→ prePD (0.311)→ PD (0.305). The increase
in the ratio was more gradual in the matrix (Figure 6),
as compared with the nigrosome, demonstrating the
following pattern of increases: AMC (0.270)→ prePD
(0.290)→ PD (0.305).
Intranuclear expression of Nox4 in dopamine neurons is
associated with intranuclear oxidative damage to nucleic
acids and activation of caspase-3
Because of our evidence demonstrating a direct link
between AngII stimulation of the AT1 and activation of
Nox4-dependent generation of superoxide in neural
stem cells [12], together with evidence by others of
prominent nuclear localization for Nox4 and Nox4-
mediated superoxide generation [31,32], we explored the
possibility that analogous interactions between the AT1
and Nox4 might occur within the nuclei of dopamine
neurons in substantia nigra of Parkinson patients. More-
over, we found co-existence of AT1 and Nox4 immuno-
reactivity in DAPI-labelled nuclei of dopamine neurons
in nigral tissue from AMC, prePD, and PD patients
(Figure 7A-C). Quantification of the percent of such
dopamine neuron nuclei that were Nox4 immunoreactive
Figure 4 Total cellular AT1 in SN dopamine neurons. (A-F) Immunodetected AT1 in the SN matrix (calbindin-rich area) from neurologically intact
patients (AMC), from prePD patients, and from PD patients. (G and H) show an example of AT1 expression in nigrosome 1 (calbindin-poor area). Scale bar
in (A-F) is 20 μm and in (G and H) is 10 μm. (I) Quantification of AT1 immunofluorescence in TH-immunopositive dopamine neurons in the SN matrix and
in nigrosome 1 as well as images (A-F) clearly illustrate dramatic reduction in the AT1 expression in nigral dopamine neurons (most profound in the matrix)
as disease progresses. In panel (I), a single asterisk identifies this AT1 immunofluorescence intensity measure as significantly different from the intensity
measures in the other two matrix groups. The double asterisk indicates a significant difference between nigrosome 1 of AMC and PD.
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whereas in prePD and in PD the nuclear Nox4 was signifi-
cantly increased and noted in 89% and in 93% of the nu-
clei examined, respectively (Figure 7D). Such increases in
the nuclear Nox4 expression were accompanied by similar
increases in oxidative stress-induced damage to neuronal
nucleic acids as demonstrated by elevated immunode-
tection of StressMarq signature of oxidized guanosine
(8-hydroxy guanosine; 8-OH guanosine) in the nuclei of
dopamine neurons (Figure 7E-G) with a progressive
pattern: 31% for AMC < 68% for prePD < 82% for PD
(Figure 7H). Taken together our measures support the
idea of nuclei-delimited pathologic changes involving
AT1→Nox4→ superoxide-induced nucleic acid dam-
age, which coincide closely with the pathologic progres-
sion in the substantia nigra from AMC→ prePD→ PD.
The degree of activation of the AT1→Nox4→
superoxide cascade correlated with immunodetectionof heightened levels of activated caspase-3, a surrogate for
an irreversible step in the apoptotic cell death pathway. In
the aged human brain, we have observed a continuum of
active caspase-3 phenotypes, such that most of the neuro-
logically normal control individuals demonstrated some,
albeit typically low, levels of active caspase-3 in dopamine
neurons (Figure 8A-C), while in prePD and PD cases
dopamine neurons displayed more intense fluorescence of
active caspase-3 (Figure 8D-I). The distribution of active
caspase-3 between the cytoplasmic and the nuclear com-
partments was also heterogeneous (Figure 8) indicating
that age-related stresses affect caspase-3 activation status
in humans.
Discussion
Here, we report that dopamine neurons from intact sub-
stantia nigra of neurologically and neuropathologically
normal patients (AMC) differ substantially with respect
Figure 5 AT1 accumulates at the nuclear envelope and within
nuclei. In dopamine neurons, AT1 is typically localized to the
cytoplasm, to the perinuclear structures (arrowheads), and to the
nuclei (A). In addition, buildup of the AT1 within nuclei identified
by arrowheads in (B) often coincides with irregularly-shaped nuclei
with chromatin irregularities identified by the arrows (C). In neurons, as
well as in some non-neuronal cells as depicted here, AT1 co-localizes
with nucleoporin 62 (p62), a component of the nuclear pore central
channel (D-G). Quantification of AT1 immunofluorescence within
nuclei of TH+ neurons in neurologically intact individuals/AMC and
in prePD and in PD patients (H) shows selective changes in AT1
corresponding to the disease progression. Notably, the abundance
of nuclear AT1 in nigrosome 1 remains constant as disease advances
whereas, in the matrix, the abundance of nuclear AT1 is gradually
reduced as a function of disease progression following the trajectory of
the total AT1 decline within the entire neuron (Figure 4I). Scale bars are
10 μm. Asterisks in (A and B) identify neuromelanin and the asterisk in
(H) identifies a significant difference between matrix of AMC and PD.
Figure 6 Ratio of nuclear to total AT1 in TH+ neurons. The ratio
was calculated by dividing the average AT1 immunofluorescence
intensity measured in the nuclei of TH+ neurons by that measured
from the entire TH+ neurons in neurologically intact individuals/AMC
and in prePD and in PD patients.
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expression of superoxide-generating Nox4, nuclear oxi-
dative stress, and cellular activation of caspase-3 from
clinically asymptomatic patients, who had only modestdopamine cell loss, but had Braak stages that were
consistent with a neuropathological diagnosis of PD
(referred to here as prePD), and from advanced PD
patients. We found that the total cellular AT1 levels
were reduced in dopamine neurons of prePD patients
as compared to age-matched neurologically normal
controls (AMC). Previously, Ge and Barnes [21] dem-
onstrated reduced radiolabelled AngII binding to the
AT1 in tissue extracts from caudate nucleus, putamen,
and substantia nigra of Parkinson patients with ad-
vanced disease compared to neurologically normal
control patients. We established that this general loss
of AT1 in substantia nigra is largely due to the reduc-
tion of AT1 in dopamine neurons, which led us to
speculate that neurons in other basal ganglia struc-
tures, namely the caudate and putamen, might also
experience a reduction in AT1. In our study, tissue
from clinically- and neuropathologically-confirmed PD
patients had greater cell loss and greater decline in the
total cellular levels of AT1 in surviving dopamine
neurons in both the calbindin-rich matrix and in the
calbindin-poor nigrosome 1 than was observed in dopa-
mine neurons from prePD patients. This pathology-
associated decline in AT1 and the accompanying in-
crease in Nox4 from AMC to prePD and finally to PD is
suggestive of a progressive loss of dopamine neurons in
nigral matrix and nigrosome 1 due to excess Nox4
generation in the nucleus of dopamine neurons and a
consequent increase in production of superoxide at
levels that precipitate nucleic acid damage leading to
neuronal dysfunction and death.
Figure 7 Intranuclear expression of Nox4 is associated with intranuclear oxidative damage to nucleic acids. Nox4 expression favors
nuclear localization in dopamine (pigmented) neurons in prePD and PD patients as compared to AMC individuals (A-C). Quantification of
the percent of dopamine neuron nuclei that are Nox4+ (D). Oxidative stress-induced damage to the nucleic acids is demonstrated by a shift
of immunohistofluorescently-detected StressMarq signature of oxidized guanosine (8-OH guanosine) into the nuclei of dopamine neurons
(E-G) – quantified in panel H. Scale bar is 20 μm. Arrows point to neurons with intranuclear expression of Nox4 or presence of StressMarq-identified
8-OH guanosine. Asterisks in (D and H) identify significant differences from AMC.
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sample to perform unbiased stereological counts for
TH+ neurons necessitated counts of all nigral TH+
neurons from just one section per patient and the
number of available patients (particularly prePD, n = 3)
resulted in relatively high standard errors, the counts
of TH+ neurons obtained corresponded closely with
the original nigrosome/matrix principles defined by
Damier and colleagues [23], in which loss of nigrosome
1 dopamine neurons is faster than the loss of such
neurons in the matrix. In that vein, we observed that in
PD as well as in prePD the density of TH+ neurons
was markedly and significantly lower in nigrosome 1 as
compared with matrix. In addition, and in agreement
with the Damier principle [23], in our patients the
density of TH+ neurons was the same in the matrix
and nigrosome 1 in AMC and followed a trend of grad-
ual decline with the disease progression. Our observa-
tion that the decline in the AT1 expression in the
matrix, a structure with a relative to nigrosome 1 spar-
ing of dopamine neurons in PD (Figure 4 and [23]), is
greater than that in the more affected nigrosome 1
where we detected a significant loss of TH+ neurons in
both prePD as well as in PD cases, suggests that prob-
ability that neurons survive increases in association
with lower total (Figure 4) as well as nuclear (Figure 5)
AT1 expression.
While, overall, the total levels of AT1 decline in dopa-
mine neurons from AMC to prePD to PD, dopamine
neurons in nigrosome 1 differ in that the ratio of nuclear
AT1 to total AT1 (nuclear + cytoplasmic +membrane)
increased stepwise from AMC to prePD to PD. Themechanistic underpinnings of the proportional increase
in nuclear AT1 in surviving dopamine neurons in
nigrosome 1 of prePD and PD patients might be related
to accompanying elevation in nuclear expression of
superoxide-generating Nox4, which in turn may explain
our finding of increased oxidative damage to DNA as
measured by elevated 8-OH guanosine (summarized in
Figure 9) and ongoing caspase-3-mediated proteolysis
and cell death. The increase in the percent of Nox4+
and StressMarq + nuclei in the context of unchanging
(or even declining in the matrix) AT1 expression might
represent a compensatory mechanism, by which cellular
stresses imposed on the dopamine neurons that might
be directly or indirectly related to changes in AT1
expression promote increases in Nox4, which is known
to be transcriptionally activated by stress and AngII [12].
Nuclear localization of Nox4 has been reported from
other cell types such as human vascular endothelial cells
[33] and from cardiomyocytes, in which Nox4 causes
histone deacetylase 4 (HDAC4) cysteine oxidation, lead-
ing to HDAC4 exit from the nucleus and cardiac hyper-
trophy [31]. Within nuclei, Nox4 has been reported to
localize to speckle domains, i.e., nuclear domains in the
interchromatin regions of the nucleus, adjacent to highly
transcriptionally active regions, suggesting that Nox4-
generated superoxide might be regulating proteins in-
volved in pre-mRNA splicing in these unique nuclear
compartments [32], underscoring the potential for Nox4
to regulate the dynamics of the nuclear gene expression
machinery. In addition to its nuclear distribution, Nox4
is often found in the mitochondria in various cell types
including neurons [34]. In cardiomyocytes, hypertrophic
Figure 8 Activation of caspase-3 corresponds to severity of PD. Immunodetection of active caspase-3 in TH-immunoreactive dopamine
neurons in the SN of AMC (A-C), prePD (D-F), and PD (G-I) patients. In an AMC case (A), arrow identifies a dopamine neuron immunopositive for
active caspase-3 in an area otherwise containing little active caspase-3. In addition, depicted are magnified views of subcellular localization of
active caspase-3 in reference to the nuclei (B, E, H) as well as of individual neurons in merged images (C, F, I). Panel (I), contains an additional
inset at the magnification of the main panel (I) illustrating vividly the boundaries of the DAPI-positive nucleus within a TH-immunoreactive
dopamine neuron to more clearly depict the extent of active caspase-3 labelling within the nucleus. Scale bar equals 50 μm (A, D, and G) or
18 μm (B, C, E, F, H, I, and inset in I). Asterisks in (C, F, and I) identify neuromelanin.
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stitutively active as its activity is principally controlled
by its expression levels, which leads to increased super-
oxide production and mitochondrial dysfunction –
events that culminate in apoptosis of cardiomyocytes
[35]. An example of the deleterious role of Nox4 in the
brain comes from studies of ischemic stroke, where
Nox4 is a major source of oxidative stress, a finding sup-
ported by the observations that pharmacological as well
as genetic inhibition of Nox4 in a mouse model of stroke
prevents oxidative stress and neurodegeneration [36]. In
addition to its role in oxidation, Nox4 promotes inflam-
mation as reported by Ginnan and colleagues in smooth
muscle cells where Nox4 is required for interleukin 1β-mediated activation of protein kinase C and of c-jun
N-terminal kinase [37].
While Nox4 can drive pathogenic pathways when
overactive, physiological activation of Nox4 is important
for maintenance of many cellular functions, including
transcription and proliferation. In that regard, the
changes noted here in AngII/AT1/Nox4 and the implicit
generation of superoxide, and in 8-OH guanosine and
its signature nucleic acid oxidation may have been elic-
ited in an attempt to protect these dopamine neurons,
and/or to stimulate regeneration, as has been reported
in the leukocyte-dependent regeneration of zebra fish
tail fin [38]. Such regeneration is dependent on produc-
tion of hydrogen peroxide, which in addition to its
Figure 9 A cell type-dependent model of interactions between AT1 and Nox1, 2, and 4 in the human substantia nigra. The AT1 is
broadly expressed in the CNS in astrocytes, microglia, and is particularly abundant in neurons, including dopamine neurons where, as we
demonstrate here, the AT1 is found not only on the plasma membrane, but also intracellularly associated with the membranes of the endoplasmic
reticulum, other cytoplasmic structures, nuclear membrane, and AT1 is found inside the nuclei themselves. The AT1 is also expressed by the vascular
smooth muscle cells and by neutrophils and macrophages, raising the possibility that brain RAS activities can be influenced by the entry of peripheral
monocyte-derived cells that are rich in AT1 and Nox2. The nuclear AT1, which we demonstrate here to be co-localized with nuclear Nox4, an event
which frequency increases with disease progression, induces intra-nuclear production of reactive oxygen species (ROS, superoxide and hydrogen
peroxide) leading to an increase in nucleic acid oxidation determined by increased levels of oxidized 8-OH guanosine (8-OHg). This complex landscape
of AT1-Nox interactions, when balanced serves to maintain tissue homeostasis and normal levels of dopamine, but in chronic disease such as
Parkinson’s the AngII/AT1/Nox4 axis might become overactive and lead to deleterious nucleic acid lesions that destabilize DNA and impair the
transcriptional machinery in the affected neurons. Taken together, our findings suggest need for additional studies of these interactions toward
designing therapies that restore healthy balance between the injurious and physiological functions of AT1 and Nox4 and by doing so moderate
progression or prevent onset of neurodegenerative diseases. Legend: neurons – Nox4 (red), microglia – Nox2 (green), and astrocytes – mixture
of Nox1 (yellow), Nox2 (green), and Nox4 (red).
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across the margin of the wound, signaling rapid recruit-
ment of leukocytes, restoration of the epithelial barrier
between the injured tissue and the outside environment
and pathogens, and stem cell proliferation for fin genesis
[38]. However, as exemplified in neurodegenerative dis-
eases in general, such mechanisms may initially be elicited
toward restoration of neuronal resilience [28,39] as we
have shown previously for AngII/AT1/Nox4-mediated
neural stem cell proliferation [12], but when neuronal
stress is prolonged overtime these mechanisms may lead,
as our findings indicate here, to oxidative damage and
loss of dopamine neurons and the frank neurological
and neuropathological manifestations of neurodegener-
ative diseases such as Alzheimer’s and Parkinson’s.
To investigate the potential for apoptotic neuronal cell
death in our AMC, prePD, and PD patients, we determined
caspase-3 activation in dopamine neurons across thesedisease stages. There are strong similarities between
historical findings of a temporal relationship between a
progressive rise in the levels of cleaved caspase-3 in both
the cytoplasmic as well as the nuclear compartments in
nigral dopamine neurons in rats injected intrastriatally
with 6-OHDA [40,41] and our findings of a stepwise
AMC<prePD<PD increase in cleaved caspase-3 in cyto-
plasm of nigral dopamine neurons that culminated in
caspase-3 expression in both cytoplasm and nucleus in
frank disease. These historical findings [40,41], together
with our findings in human tissue are indicative of an
AngII/AT1/Nox4-superoxide axis that contributes to, and
thus may be responsible for, the progressive dysfunction
and loss of dopaminergic neurons that underlie the neuro-
pathological changes and neurological failures characteris-
tic of Parkinson’s.
Inquest into brain angiotensin-regulated pathways raises
a question of why components of RAS are expressed in
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regulation between RAS and dopamine as a principal
reason, where, as we hypothesize, the increase in AngII
signaling via AT1 might directly promote dopaminergic
neurotransmission by increasing the activity of TH, as
was demonstrated outside the brain in organs such as
the kidney [42]. Additional support for angiotensin↔
dopamine counterregulation comes from experiments
in rats, where depletion of dopamine with an inhibitor
of TH, reserpine, resulted in an increase in AT1 at both
mRNA and protein levels [43]. In parallel experiments
in which similar increases in AT1 were achieved with
6-OHDA administration, co-administration of L-dopa
prevented such increases in AT1 [43]. In our study, in
contrast to the prePD patients who were not treated
with L-dopa, in L-dopa-medicated advanced PD pa-
tients, the L-dopa treatment might have affected the
AT1 expression profiles. One could speculate that such
effects could potentially include L-dopa promoting low-
ering of membrane and cytoplasmic AT1 expression
while lacking an effect on the nuclear AT1 – a pattern
of AT1 expression changes that we have demonstrated
in the current study. Further studies of the L-dopa
effects on the RAS are needed to illuminate these
important angiotensin↔dopamine counterregulatory
mechanisms in the human brain. Such studies should
also consider potential contributions of other biological
processes on the regulation of AT1 expression. In addition
to L-dopa-regulation of AT1 levels, other molecular
entities and biological processes affect AT1 levels. For
example, elevation of AngII/AT1 also occurs in rodents
with: i) advancing age [17], ii) reduction in estrogen mod-
eling menopause [44], and iii) hypoperfusion of the brain
[45]. Central activity of AngII has also been reported to be
elevated in conditions that compromise blood–brain
barrier (BBB), such as neurogenic hypertension, permit-
ting circulating AngII access to the CNS [46]. Such
effects of the circulating AngII on the CNS were also
demonstrated in rats with mannitol-mediated experi-
mental disruption of the BBB, which resulted in circu-
lating AngII gaining access to the rostral ventrolateral
medulla; there AngII increased activation of dopamine
neurons assayed by an increase in c-Fos immunoreac-
tivity in TH-immunopositive neurons [47].
The idea of altering the activity of RAS for therapeutic
benefit in Parkinson’s was first tested in Melbourne by
demonstrating in a prospective study that the angio-
tensin converting enzyme (ACE) inhibitor, perindopril,
reduces levodopa-induced dyskinesias [48]. Subsequently,
progress in elucidating the potential role of AngII/AT1
interactions in Parkinson neuropathogenesis has been
greatly aided by the development of MPTP- and 6-
OHDA-rodent models of Parkinson’s [4,18]. Treatment of
rodents with blockers of AT1 (ARBs) before administrationof either MPTP or 6-OHDA prevents neurotoxic ef-
fects of these agents through less microglial activation,
less generation of NADPH oxidase (e.g., Nox4) and
therefore less superoxide production, and less neuronal
dysfunction and loss, suggesting that ARBs promote
dopamine neuron resilience and survival. The insights
gained from the rodent studies have now been validated
in humans by Lee and colleagues who report in a study
of 65,000 neurologically normal hypertensive patients
that use of high cumulative doses of ARBs is associated
with reduced risk of developing Parkinson’s when
compared to the use of β blockers [49]. The beneficial
effects of ARBs on human CNS neurons extend beyond
Parkinson’s. As a matter of fact, among Alzheimer
patients treated with ARBs the incidence of Alzheimer
is less and there is less Alzheimer neuropathology
[50,51]. Moreover, cognition is improved [50,52].These
findings in patients, together with studies of animal
models of Parkinson’s and Alzheimer’s [4,18,53], suggest
that downregulation of the AngII/AT1-driven cascades
may, in general, confer neuronal protection. Whether such
interactions are part of the initiation and progression of
the neuropathological changes in dopamine neurons that
are associated with Parkinson’s is, at present, unclear.
Furthermore, if such events are part of Parkinson’s
pathogenesis, whether and/or how intervention to modify
AngII/AT1 interactions may circumvent or delay onset
of Parkinson neuropathogenesis is unknown. To our
knowledge, this present report is first to demonstrate
the cellular and subcellular distribution of AT1 and
Nox4 relative to Parkinson’s disease progression.
Our examination of nuclear morphology showed spe-
cific changes that correlated with disease progression.
The nucleus is the largest organelle in a dopamine
neuron and has intricate connections to the cytoskeleton
that maintain topographical and functional nucleo-
cytoskeletal interdependence [54]. In addition, changes
in nuclear shape and size are associated with diseases
such as cancer as well as with aging [55,56]. We have
noted a potential disruption of normal nuclear morph-
ology in dopamine neurons coincident with accumu-
lations of aberrantly-expressed assemblies containing
nuclear deposits of AT1 and Nox4 infiltrating deep into
the nuclei of affected dopamine neurons. In most such
affected neurons, these AT1/Nox4 accumulations in-
filtrate nuclei from only one side along the nuclear
long axis. Whether such nuclear accumulations disrupt
structure-dependent molecular interactions and gene
expression profiles by destabilizing normal regulation of
nuclear processes such as molecular crowding, which
controls diffusion and interactions of nuclear proteins
with heterochromatin [57,58], and thereby accelerate
the advance of neurodegenerative disease pathology and
neuronal dysfunction, is unknown. By analogy to our
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filamentous tau deposits that span the nuclear long axis
and are referred to as “tau nuclear rods” have been
reported from neurons in the striatum and in the cortex
of Huntington patients and in the hippocampal neurons
in Alzheimer patients [59]. Although tau nuclear rods
are hypothesized by some to be harmless signatures
of altered microtubule dynamics, other investigators
propose that tau nuclear rods could compromise the
integrity of the nuclear membrane promoting nuclear
fragmentation and cell death [59]. The previously
unrecognized patterns of proportional increases in
nuclear AT1 in dopamine neurons in nigrosome 1 of
prePD and PD patients that we observed might under-
score a surge in neurooxidative and neuroinflammatory
processes favoring increased intranuclear stress and oxi-
dative damage to nucleic acids leading to promulgation
of untoward transcriptional changes. Hypothetically,
such aberrant nuclei could arise from the disease
process-related topographic modulation of the nuclear
shape – a feature that might serve as a surrogate of
pathologic progression in Parkinson’s. Future studies of
AT1/Nox4 nuclear buildup should examine changes to
the nuclear geometry and nucleo-cytoskeletal dynamics
using quantitative nuclear morphometry and interro-
gate these nuclear features for association with changes
in gene expression patterns.
Unlike many studies that report expression changes
from only subjective ranking or from small numbers of
cells, we have dedicated a substantial effort to assure
that AT1 expression was measured in a highly controlled
and reproducible fashion in a large number of TH+ neu-
rons. The quantification method employed by us utilized
Nikon Element’s data analysis software intensity mea-
surements that have been used and confirmed against
other methods for protein expression analysis (Western
immunoblot and ELISA) by us and other groups and
published in a number of reports [26,28,60]. In addition,
detailed examination by two blinded evaluators of the
computer-generated AT1 signal intensity measured
corresponded reliably with the visual examination of the
same cells in corresponding photomicrographs. Despite a
series of important changes in expression and localization
of AT1 that we found to be associated with disease pro-
gression, our study has limitations including low numbers
of prePD patients (n = 3) and use of immunohistofluores-
cence as a sole method for AT1 quantification. Practical
reasons including the fact that presymptomatic patients
demonstrating Braak stages and dopamine neuron loss
consistent with early PD are difficult to find and that the
brain tissues from these patients were available only in the
form of paraffin-embedded tissue blocks necessitated
the present study design. Future studies will focus on
identification of a larger cohort of prePD patients inwhom RAS-related biomarkers of early disease can be
examined further using in addition to immunohisto-
chemical methods, multiplex gene expression profiling
and biochemical protein analysis approaches.
The evolutionary advantage of increasing AngII/AT1
activity might reflect the brain’s attempt to counteract
the deficits in dopaminergic neurotransmission that
accompany progression of Parkinson’s disease, and con-
currently, via the AngII/AT1/Nox4 pathway increase
neurogenesis as a measure to replace neurons being
lost. Our current study and earlier investigations in ani-
mal models as well as by means of clinical studies with
ARBs demonstrated a fundamental role for the AT1 in
Parkinson’s and Alzheimer’s, but as of yet have not
explored other molecular players in the complex net-
work of brain RAS. These players include at least four
other angiotensins (AngIII, AngIV, Ang1–7, and Ang3–7)
in addition to AngII; another ACE, namely ACE2; as
well as four additional receptors, namely AT2, AT4,
Mas, and pro-renin receptors, extending substantially
the RAS-related receptor field beyond the AT1 (for re-
view see [61]). Although examination of these additional
components of RAS was certainly beyond the scope
of the current study, investigations that will take place
during the next decade will offer novel insights into
the complex regulation of the brain RAS and will en-
gineer means for modulating RAS activity for disease-
modification or perhaps even prevention in Parkinson’s,
Alzheimer’s, and beyond.
Conclusions
Using semiquantitative immunohistofluorescence, we
found that AT1 protein expression in dopamine neurons
of the human substantia nigra is reduced with the
disease progression from AMC → prePD → PD in the
calbindin-rich matrix and in the calbindin-poor nigrosome
1, where we observed greater loss of TH-immunopositive
dopamine neurons. In all cases examined, the AT1 was
primarily associated with the intracellular structures
within the cytoplasm as well as with the nuclear envelope
and nuclear pore complexes, as determined by colocaliza-
tion of the AT1 with nucleoporin p62, and deep within
the nuclei of dopamine neurons. Although the nuclear
AT1 in dopamine neurons located in the matrix demon-
strated a similar loss of AT1 corresponding with the
clinicopathological progression as was observed for the
entire neuron AT1, the nuclear AT1 in the nigrosome
1 dopamine neurons did not show reduction and
remained at levels characteristic of the neurologically
and neuropathologically normal control patients. There-
fore, we propose that such a nonphysiological shift in the
cytoplasmic and nuclear AT1 distribution in favor of
nuclear AT1 increases oxidative damage to DNA. Such
a scenario is supported by the observed colocalization
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and with 8-OH guanosine-detected oxidative damage to
the nucleic acids. Disease progression from AMC →
prePD → PD was also associated with increases in
Nox4, oxidative damage to DNA, and activation of
caspase-3 in the nuclei of dopamine neurons, giving
support to the idea that an AngII/AT1/Nox4-super-
oxide axis contributes to the neurooxidative injury in
dopamine neurons and underscoring the need for
further studies of modifiers of the brain RAS activity for
preventive and/or symptomatic treatment of neurode-
generative diseases.
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